First Trust Direct Indexing’s BioMarin Pharmaceuticals BMRN Stock Holding History

First Trust Direct Indexing’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,984	Closed	-$432K	–	703
2023 Q2	$432K	Sell	4,984 -889	-15%	-$83.7K	0.05%	452
2023 Q1	$571K	Buy	5,873 +132	+2%	+$13.7K	0.07%	362
2022 Q4	$594K	Buy	5,741 +820	+17%	+$77K	0.08%	323
2022 Q3	$417K	Buy	4,921 +91	+2%	+$8.1K	0.06%	388
2022 Q2	$400K	Buy	4,830 +559	+13%	+$44.5K	0.06%	397
2022 Q1	$329K	Buy	4,271 +290	+7%	+$24.3K	0.04%	474
2021 Q4	$352K	Buy	3,981 +153	+4%	+$12.6K	0.05%	452
2021 Q3	$296K	Buy	3,828 +874	+30%	+$69K	0.04%	477
2021 Q2	$246K	Buy	+2,954	New	+$234K	0.04%	511
2021 Q1	–	Sell	-1,849	Closed	-$162K	–	470
2020 Q4	$162K	Buy	+1,849	New	+$147K	0.04%	391

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

First Trust Direct Indexing's BMRN Position: Q3 2023 in Review

First Trust Direct Indexing sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 4,984 shares — an estimated $432K sold.

First Trust Direct Indexing first reported a position in BMRN in Q4 2020 and held it in 10 quarters. The position peaked at $594K in Q4 2022. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

First Trust Direct Indexing reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
First Trust Direct Indexing sold 4,984 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $432K.
First Trust Direct Indexing first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 10 quarters.
First Trust Direct Indexing's BioMarin Pharmaceuticals position peaked at $594K in Q4 2022.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on First Trust Direct Indexing's 13F filing for Q3 2023, filed 30 Oct 2023.